The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages

No abstract is available for this paper.

• Publication year

  1993

• Venue

  European Journal of Immunology

• Publication date

  1993-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/eji.1830231210PMID 8258324
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone marrow cells in X-linked agammaglobulinemia express pre-B-specific genes (lambda-like and V pre-B) and present immunoglobulin V-D-J gene usage strongly biased to a fetal-like repertoire.

  1993cited by this paper
• The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

  1993cited by this paper
• Diversity of immunoglobulin kappa light chain gene rearrangements and evidence for somatic mutation in V kappa IV family gene segments in X-linked agammaglobulinemia.

  1993cited by this paper
• Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

  1993cited by this paper
• Differential usage of T cell receptor V gene segments in CD4+ and CD8+ subsets of T lymphocytes in monozygotic twins.

  1993cited by this paper
• The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

  1993cited by this paper
• Diversity of immunoglobulin χ light chain gene rearrangements and evidence for somatic mutation in VχIV family gene segments in X‐linked agammaglobulinemia

  1993cited by this paper
• Genetic linkage analysis identifies new proximal and distal flanking markers for the X-linked agammaglobulinemia gene locus, refining its localization in Xq22.

  1993cited by this paper
• Evidence for a human IgG1 class switch program

  1993cited by this paper
• Immunoglobulin x light chain germ‐line transcripts in human precursor B lymphocytes

  1992cited by this paper
• Diversity of immunoglobulin heavy chain gene segment rearrangement in B lymphoblastoid cell lines from X‐linked agammaglobulinemia patients

  1991cited by this paper
• X-linked agammaglobulinemia.

  1991cited by this paper
• Evidence that in X‐linked immunodeficiency with hyperimmunoglobulinemia M the intrinsic immunoglobulin heavy chain class switch mechanism is intact

  1990cited by this paper
• Severe combined immunodeficiency in man with an absence of immunoglobulin gene rearrangements but normal T cell receptor assembly

  1990cited by this paper
• Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia.

  1990cited by this paper
• Clonal diversity in the B cell repertoire of patients with X-linked agammaglobulinemia

  1989cited by this paper
• Rearrangement and expression of T-cell receptor delta genes in T-cell acute lymphoblastic leukemias.

  1989cited by this paper
• Immunophenotyping of leukaemias and non-Hodgkin's lymphomas. Immunological markers and their CD codes.

  1988cited by this paper
• Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells.

  1988cited by this paper
• Human leukemia cell lines--clinical and theoretical significances.

  1988cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Leukocyte Typing II

  1986cited by this paper
• Immunoglobulin heavy chain gene rearrangements in X‐linked agammaglobulinemia

  1986cited by this paper
• [Malignant lymphomas].

  1985cited by this paper
• Lithotripsy. Health and Public Policy Committee, American College of Physicians.

  1985cited by this paper
• A glyceraldehyde‐3‐phosphate dehydrogenase pseudogene on the short arm of the human X chromosomes defines a multigene family.

  1984cited by this paper
• Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment

  1982cited by this paper
• Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes.

  1982cited by this paper
• Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes

  1982cited by this paper
• Agammaglobulinemia.

  1952cited by this paper

• Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

  2026cites this paper
• Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton's Tyrosine Kinase (BTK) Inhibitors.

  2025cites this paper
• Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials

  2025cites this paper
• Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

  2024cites this paper
• BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

  2024cites this paper
• Identification of a pharyngeal mucosal lymphoid organ in zebrafish and other teleosts: Tonsils in fish?

  2023cites this paper
• Identification of a new pharyngeal mucosal lymphoid organ in zebrafish and other teleosts: tonsils in fish?

  2023cites this paper
• Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions

  2023cites this paper
• Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings.

  2023cites this paper
• Cardiotoxicity of BTK inhibitors: ibrutinib and beyond

  2022cites this paper
• Bruton’s Tyrosine Kinase Deficiency Ameliorates Antimicrobial Host Defense during Peritonitis Induced by Pathogenic Escherichia coli

  2022cites this paper
• BTK, the new kid on the (oncology) block?

  2022cites this paper
• Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments

  2022cites this paper
• Novel Bruton’s Tyrosine Kinase (BTK) substrates for time-resolved luminescence assays

  2022cites this paper
• BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

  2022cites this paper
• Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

  2021cites this paper
• Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

  2021cites this paper
• Leukemia: Trends in treatment and how close we have achieved eradication

  2021cites this paper
• Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease

  2021cites this paper
• Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis.

  2021cites this paper
• Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia

  2021cites this paper
• Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors

  2021cites this paper
• Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response

  2021cites this paper
• Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.

  2021cites this paper
• Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.

  2021cites this paper
• Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

  2021cites this paper
• Discovery of novel BTK PROTACs for B-Cell lymphomas.

  2021cites this paper
• Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

  2020cites this paper
• Emerging drugs for the treatment of Waldenström macroglobulinemia

  2020cites this paper
• The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia

  2020cites this paper
• Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy

  2020cites this paper
• A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors

  2020cites this paper
• Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.

  2020cites this paper
• Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer

  2020cites this paper
• OTT_A_245848 4113..4122

  2020cites this paper
• Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases

  2020cites this paper
• Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC‐MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats

  2019cites this paper
• Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review

  2019cites this paper
• Current Clinical Trials in Pemphigus and Pemphigoid

  2019cites this paper
• A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)

  2019cites this paper
• The Molecular Physiology of Ageing: New Targets for Regenerative Medicine

  2019cites this paper
• Invasive fungal infections in the immunocompromised host: Mechanistic insights in an era of changing immunotherapeutics.

  2019cites this paper
• Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease

  2019cites this paper
• Disturbed Transcription of TLRs’ Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients

  2019cites this paper
• From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

  2019cites this paper
• Workup of Recurrent Respiratory Infections and a Positive Family History

  2019cites this paper
• Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.

  2018cites this paper
• Studies of Bruton’s tyrosine kinase inhibitors in B-cell malignancies

  2018cites this paper
• 1 Activity of ibrutinib , a BTK inhibitor , in patients with CD 117 positive acute myeloid leukaemia – a pre-clinical study

  2018cites this paper
• First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.

  2018cites this paper
• Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus

  2018cites this paper
• Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma

  2018cites this paper
• Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors

  2018cites this paper
• Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains

  2018cites this paper
• Evaluation of Experimental Infection with L. (L.) Amazonensis in X-Linked Immunodeficient Mice

  2018cites this paper
• Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

  2017cites this paper
• This information is current as SignalingKinase and BTK in B Cell Receptor Distinct and Overlapping Functions of TEC Ellmeier

  2017cites this paper
• Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold

  2017cites this paper
• Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization.

  2017cites this paper
• Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

  2017cites this paper
• Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling

  2017cites this paper
• Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

  2017cites this paper
• Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors

  2017cites this paper
• Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.

  2017cites this paper
• A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

  2016cites this paper
• Btk and NFκB as prognostic biomarkers and potential therapeutic targets in B cell acute lymphoblastic leukemia

  2016cites this paper
• Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.

  2016cites this paper
• Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.

  2016cites this paper
• Preclinical Evaluation of Synergistic Drug Combinations in Acute Myeloid Leukemia

  2016cites this paper
• Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism

  2015cites this paper
• Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer

  2015cites this paper
• Splice-Correction Strategies for Treatment of X-Linked Agammaglobulinemia

  2015cites this paper
• Role of Bruton’s tyrosine kinase inhibitors in HIV-1-infected cells

  2015cites this paper
• Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.

  2015cites this paper
• The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

  2015cites this paper
• Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.

  2015cites this paper
• Design and application of RNA therapeutics for splice site mutations

  2015cites this paper
• Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma

  2015influential citation
• Composés hétérocycliques destinés à être utilisés dans le traitement de troubles médiés par pi3k-gamma

  2015cites this paper
• Novel Therapeutic Options for X-Linked Agammaglobulinemia

  2015cites this paper
• B‐cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

  2015cites this paper
• Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

  2014cites this paper
• Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML

  2014cites this paper
• Ibrutinib and indolent B-cell lymphomas.

  2014cites this paper
• Evolution of the Definition of Primary Immunodeficiencies

  2014cites this paper
• Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.

  2014cites this paper
• Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

  2014cites this paper
• A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

  2014cites this paper
• Brutonˈs tyrosine kinase—an integral protein of B cell development that also has an essential role in the innate immune system

  2014cites this paper
• Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia

  2014cites this paper
• BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future

  2014cites this paper
• Targeting Bruton's tyrosine kinase in B cell malignancies

  2014cites this paper
• Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

  2014cites this paper
• Bruton's Tyrosine Kinase: Structure and Functions, Expression and

  2013cites this paper
• Modulation of NK/NKT Cell Responses via Francisella tularensis with Virulent B1a Cells Enhance Susceptibility to Infection

  2013cites this paper
• Novel Bruton’s tyrosine kinase inhibitors currently in development

  2013influential citation
• promoter via NF- Proteasome dependent auto-regulation of Bruton's tyrosine kinase (Btk)

  2013cites this paper
• Regulatory functions of the actin cytoskeleton in B cell receptor signaling

  2013cites this paper
• B1a Cells Enhance Susceptibility to Infection with Virulent Francisella tularensis via Modulation of NK/NKT Cell Responses

  2013cites this paper
• Ibrutinib and novel BTK inhibitors in clinical development

  2013cites this paper